Respiratory diseases

Organism
TB
mycobacterium

N. meningitides

vaccine
BCG

Type

Dose

Newborn: .05ml
Live
attenuated Adult: .1ml

Purified polysaccharides
Monovalent (A or C)
Bivalent (A and C)
Polyvalent (A,C,y,W135)`

Varicella
(chickenpox)

Intradermal in left deltoid

Subcutaneous injection

Live attenuated

Influenza

Administration

Intranasal
IM
Adult: in deltoid once annually
Children: in ant lat. aspect of thigh twice
separated by 4 weeks

Inactivated

Live attenuated

.5ml

Subcutaneous injection
Children: single dose
Above 13y: 2doses of 4-8weeks apart

Mumps
measles
Rubella

Monovalent or
combined (MMR)

Live
attenuated

Subcutaneous injection in Rt. arm Single

dose(compulsory vaccine in EGYPT at age 12,
18m)

Effectiveness

Indications

High prevalence: all births

Low prevalence: high risk groups
Health care workers
Contacts ve tuberculin test
Workers exposed to silica
Military recruits
Immunity start after 3days
School children
Last for 3 years
Travelers to endemic areas
Need booster doses every 3 years
Pilgrimage
Community outbreaks
Healthy persons 5-49y
Persons above 65y
Immunosuppression (HIV)
70-90% and immunity decline after 1 Children, adolescent receiving long
year
term aspirin therapy
Chronic debilitating diseases
Health care workers
Children 18m-12y with no previous
vaccination
85-90% disease prevention
Contacts
100% severity prevention
Health care workers
Teachers
Single dose 95% detectable Ab Health care workers
Military personnel
Immunity develops after 8d
protect 95% of recipients
Women in postpartum period
Long period immunity
Teachers
Health care workers
80% prevention of TB meningitis,
military TB in children
Decrease progression to active
disease in adults

GIT diseases

Organism vaccine
Old
(conventional)

Type
Killed whole cell

Dose

WC/rBS

2 oral doses of 1 or 2 weeks apart

Salk (IPV)

formalin killed (3 strains)

SC or IM 2-3 doses in 1st year

Sabin (OPV)

Live attenuated (3 strains)

HBV

HBV

TAB

Recombinant HBsAg

2 drops

Adult: 1ml
2-18y: .5ml

.5ml

Heat-phenol inactivated
Purified Vi polysaccharide

Typhoid
Ty21a

Live attenuated

Indications
No longer recommended now

Travelers to endemic areas

Poliomyelitis

Formalin inactivated

Effectiveness
Limited protection 50%
Short duration 3-6m
Highly effective (90%) and
extremely immunogenic

Single oral dose

Heat or formalin killed whole

cell with purified
recombinant B-subunit of
cholera toxoid

HAV

Boosters

Subcutaneous 2 doses, 4 weeks apart

Live attenuated
Vibrio cholera

Administration

one capsule

after 2y

high protection 85-90% for 6m

Induce circulatory Ab but no intestinal immunity

Prevent paralysis but reinfection can occur
Induce both circulatory and intestinal Ab
Oral 6 doses at birth, 2,4,6,9,12m
at 18m
Prevent paralysis and intestinal reinfection
Travelers to endemic areas
(1M prior to travel)
Children > 2y in endemic areas
Patients of clotting factors
Highly immunogenic >95%
IM in deltoid 2doses, 6-12m apart
disorders
protection within one month
Patients of chronic liver
disease
Food handlers
In outbreaks
Health care workers
Patients need repetitive blood
transfusion or clotting factors
Patients on hemodialysis
IM in deltoid (adults), ant lat.
for hemodialysis
Infants
Aspect of the thigh (infants)
Immunity persist for at least 15y
patients
Infants born to infected
3 doses at 1m, 6m, later
mothers
Sexual contacts of HBV
patients of carriers
Prisoners
SC 2 doses, 4 weeks apart at 6m
Every 3 y
Travelers to endemic areas
SC one dose at 2y
Every 2 y
Those who living in endemic
area
Every year for travelers
House hold members of
to endemic areas
Oral 3 doses, 2d apart at 6y
known carriers
Every 5y to those living
in endemic areas
Health care workers
4-6 y